Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Versartis Inc. (VSAR): Perceptive Advisors Raises Stake

Page 1 of 8

According to a recent 13G filing with the US Securities and Exchange Commission, Joseph Edelman‘s Perceptive Advisors has increased its stake in Versartis Inc. (NASDAQ:VSAR) to 4.03 million common shares, which account for 13.63% of the float. The stake was raised from 2.84 million shares Perceptive Advisors previously held at the end of June,  according to its last 13F filing.

Versartis is a biopharmaceutical company that primarily works on producing long-acting therapeutics for treating endocrine illnesses. Over the past 12 months, the company’s stock has gained 8.41%. In its last financial report for the second quarter of 2016, Versartis disclosed a net loss of $22.1 million and a loss per share of $0.75, which compares to a net loss of $19.7 million, and a loss per share of $0.67 for the corresponding quarter in the previous year. Recently Piper Jaffray Cos. initiated coverage on Versartis’ stock and placed an ‘Overweight’ rating on it, with a price target of $22.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


Six smart money managers from Insider Monkey’s database reported long positions in Versartis (NASDAQ:VSAR) at the end of June, versus seven funds in an earlier quarter. Among bullish investors were Julian Baker And Felix Baker’s Baker Bros. Advisors, with a position valued at $30.12 million, Dennis Purcell’s Aisling Capital, which held a position valued at $25.21 million, Chuck Royce’s Royce & Associates, Mark Kingdon’s Kingdon Capital Management, and D. E. Shaw’s D E Shaw. An investor who dumped Versartis (NASDAQ:VSAR) during June quarter was Israel Englander’s Millennium Management, which said goodbye to $701,000 worth of shares.

Follow Versartis Inc. (NASDAQ:VSAR)
Trade (NASDAQ:VSAR) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Perceptive Advisors 0 4,028,685 0 4,028,685 13.63%
Joseph Edelman 0 4,028,685 0 4,028,685 13.63%
Perceptive Life Sciences Master Fund, Ltd 0 3,871,286 0 3,871,286 13.1%

Joseph Edelman
Joseph Edelman
Perceptive Advisors

Page 1 of 8 – SEC Filing


Washington, D.C. 20549


the Securities Exchange Act of 1934

Versartis, Inc.

of Issuer)



of Class of Securities)





28, 2016

of Event Which Requires Filing of this Statement)


Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:


x Rule
x Rule
o Rule


remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.


information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).


who are to respond to the collection of information contained in this form are not required to respond unless the form displays
a currently valid OMB control number.

Follow Versartis Inc. (NASDAQ:VSAR)
Trade (NASDAQ:VSAR) Now!
Page 1 of 8

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!